Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F14%3A10293159" target="_blank" >RIV/00064203:_____/14:10293159 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/14:10293159

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.urolonc.2013.07.006" target="_blank" >http://dx.doi.org/10.1016/j.urolonc.2013.07.006</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.urolonc.2013.07.006" target="_blank" >10.1016/j.urolonc.2013.07.006</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma

Popis výsledku v původním jazyce

Objectives: Evidence suggests a positive effect of metfoimin on cancer incidence and outcome. To date, the effect of metfoimin use on prognosis in urothelial carcinoma of the bladder (UCB) remains uninvestigated. We tested the hypothesis that metformin use affects oncologic outcomes of patients treated with radical cystectomy for UCB. Methods and materials: We retrospectively evaluated 1,502 patients treated at 4 institutions with radical cystectomy and pelvic lymphadenectomy without neoadjuvant therapy. Cox regression models addressed the association of diabetes mellitus (DM) and metformin use with disease recurrence, cancer-specific mortality, and any-cause mortality. Results: A total of 200 patients (13.3%) had DM, 80 patients (5.3%) used metformin.Within a median follow-up of 34 months, 509 patients (33.9%) experienced disease recurrence, 402 patients (26.8%) died of UCB, and 551 patients (36.7%) died from any cause. In univariable Cox regression analyses, DM without metfonnin use

Název v anglickém jazyce

Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma

Popis výsledku anglicky

Objectives: Evidence suggests a positive effect of metfoimin on cancer incidence and outcome. To date, the effect of metfoimin use on prognosis in urothelial carcinoma of the bladder (UCB) remains uninvestigated. We tested the hypothesis that metformin use affects oncologic outcomes of patients treated with radical cystectomy for UCB. Methods and materials: We retrospectively evaluated 1,502 patients treated at 4 institutions with radical cystectomy and pelvic lymphadenectomy without neoadjuvant therapy. Cox regression models addressed the association of diabetes mellitus (DM) and metformin use with disease recurrence, cancer-specific mortality, and any-cause mortality. Results: A total of 200 patients (13.3%) had DM, 80 patients (5.3%) used metformin.Within a median follow-up of 34 months, 509 patients (33.9%) experienced disease recurrence, 402 patients (26.8%) died of UCB, and 551 patients (36.7%) died from any cause. In univariable Cox regression analyses, DM without metfonnin use

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Urologic Oncology: Seminars and Original Investigations

ISSN

1078-1439

e-ISSN

—

Svazek periodika

32

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

—

Kód UT WoS článku

000347243300098

EID výsledku v databázi Scopus

—